AA
EFTR

ALPS Advisors’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

ALPS Advisors’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,861
Closed -$187K – 1097
2022
Q1 		$187K Sell
1,861
-217
-10% -$28.8K ﹤0.01% 807
2021
Q4 		$430K Buy
+2,078
New +$482K ﹤0.01% 590

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
ECM
Evolution Capital Management Crystal Bay, Nevada $29M AUM 2.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

ALPS Advisors's EFTR Position: Q2 2022 in Review

ALPS Advisors sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2022, closing a stake of 1,861 shares — an estimated $187K sold.

ALPS Advisors first reported a position in EFTR in Q4 2021 and held it in 2 quarters. The position peaked at $430K in Q4 2021. 24 funds tracked by Wall St. Rank hold EFTR as of Q2 2022.

  • ALPS Advisors reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 1,861 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $187K.
  • ALPS Advisors first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • ALPS Advisors's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $430K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.